Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center

Journal of Drugs in Dermatology

Volumn 12, Issue 8, 2013, Pages 861-866

  Au, Shiu Chung ^a   Madani, Abdulaziz ^a   Alhaddad, Marwan ^a   Alkofide, Maha ^a   Gottlieb, Alice B ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PSORALEN DERIVATIVE; USTEKINUMAB;

ARTICLE; BIOLOGICAL THERAPY; BODY SURFACE; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DERMATOLOGIST; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; PHOTOTHERAPY; PHYSICIAN GLOBAL ASSESSMENT; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; RETROSPECTIVE STUDY; SIMPLE MEASURE FOR ASSESSING PSORIASIS ACTIVITY; SYSTEMIC THERAPY; TREATMENT DURATION; ULTRAVIOLET B RADIATION;

CROSS-SECTIONAL STUDIES; DERMATOLOGIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; PHOTOTHERAPY; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84882445789     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Farber EM, NL. Epidemiology: natural history and genetics., in Psoriasis, M.H. Roenigk HR Jr, Editor. 1998, Marcel: Dekker, New York. p 107-157.
2. Raychaudhuri, S.P. and E.M. Farber, The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol. 2001, 15(1): p 16-7.
3. Mrowietz U et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011, 303(1): p 1-10.
4. Liem WH, McCullough JL, and Weinstein GD. Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis. 1995. 55(5): p 306-10.
5. Stern RS et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004, 9(2): p 136-9.
6. Iyer S, Yamauchi P, and Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol. 2002. 146(1): p. 118-21.
7. Saurat JH et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008, 158(3): p 558-66.
8. Reich K et al. Infliximab induction and maintenance therapy for moderateto-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005, 366(9494): p 1367-74.
9. Boyce EG, Halilovic J, and Stan-Ugbene O. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-alpha inhibitor. Clin Ther. 2010, 32(10): p 1681-703.
10. Menter A et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008, 58(5): p 826-50.
11. Duvallet E et al. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med. 2011, 43(7): p 503-11.
12. Croxtall JD. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs. 2011, 71(13): p 1733-53.
13. Gottlieb A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009, 373(9664): p 633-40.
14. Herrier RN. Advances in the treatment of moderate-to-severe plaque psoriasis. Am J Health Syst Pharm. 2011, 68(9): p 795-806.
15. Kamangar, F., et al., How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center. J Dermatology Treat. 2013, 24(1): p 13-24.
16. Dommasch ED et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011, 64(6): p 1035-50.
17. Castela E et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol. 2012, 26 Suppl 3: p 36-46.
18. Castela E et al. Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. J Eur Acad Dermatol Venereol. 2012, 26 Suppl 3: p 47-51.
19. Anstey AV and Kragballe K. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol. 2006, 45(8): p 970-5.
20. Devaux S et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012, 26 Suppl 3: p 61-7.
21. Kanwar AJ, Yadav S, and Dogra S. Psoriasis: what is new in nonbiologic systemic therapy in the era of biologics? Indian J Dermatol Venereol Leprol. 2010. 76(6): p 622-33.
22. Menter A et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009, 61(3): p 451-85.
23. Naldi L et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol. 2003, 120(5): p 738-41.
24. Naldi L et al. Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001-2006. Br J Dermatol. 2010, 162(2): p 384-9.
25. Menter A et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011, 65(1): p 137-74.
26. Gelfand JM et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012, 148(4): p 487-94.
27. Dommasch EWJ Woodcock J Shin D Duffin K Gelfand J. Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA), in World Congress Dermatology. May 2011: Seoul Korea.
28. Administration FaD. Enbrel (etanercept) for the treatment of pediatric plaque psoriasis. June 18, 2008. [cited 2013 January 20]; Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4361b2-01-FDA.pdf.
29. Kurd SK and Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009, 60(2): p 218-24.
30. Parisi R et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013, 133(2): p 377-85.
31. Kristensen LE et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis. 2008, 67(3): p 364-9.
32. Greenberg JD et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010, 69(2): p 380-6.
33. Driessen RJ et al. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol. 2009, 160(3): p 670-5.
34. Puig L. Treatment of severe psoriasis. J Eur Acad Dermatol Venereol. 2012, 26 Suppl 5: p 17-8.
35. Guenther LC. Combination therapy of biologics with traditional agents in psoriasis. Skin Therapy Lett. 2011, 16(6): p 1-3.
36. Marquez C et al. Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. J Drugs Dermatol. 2010, 9(7): p 753-8.
37. Gottlieb AB et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012, 167(3): p 649-57.
38. Bailey EE et al. Combination treatments for psoriasis: a systematic review and meta-analysis. Arch Dermatol. 2012, 148(4): p 511-22.
39. Hu J et al. The frequent use of oral retinoids in combination with other treatments for psoriasis: a retrospective analysis. J Cutan Med Surg. 2004, 8(6): p. 411-4.
40. Faerber L et al. Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients. Am J Clin Dermatol. 2001, 2(1): p 41-7.
41. Ho VC et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 2001, 44(4): p 643-51.
42. Berth-Jones J et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study. Br J Dermatol. 1997, 136(4): p 527-30.
43. Robinson, A., M. Kardos, and A.B. Kimball, Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012, 66(3): p 369-75.
44. Spuls, PI, et al. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010, 130(4): p 933-43.
45. Puzenat, E, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010, 24 Suppl 2: p 10-6.
46. Bonafede, M, et al. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012, 29(8): p 664-74.
47. Chastek, B, et al. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan. Adv Ther. 2012. 29(8): p 691-7.